DGX — Quest Diagnostics Incorporated

Quest Diagnostics Incorporated (DGX) is a diagnostics & research company listed on NYSE. It is led by James E. Davis, based in 500 Plaza Drive, Secaucus, NJ, United States, 07094, with about 55,000 employees. Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, emerging retail healthcare providers, pharmaceutical companies and insurers, commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Latest reported DGX revenue for 2025-09-30 was $2.82B. Net income was $259.0M. Revenue was up 2.0% from 2025-06-30 to 2025-09-30. DGX currently screens at market cap $19.94B and trailing P/E 22.4.

Use this DGX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the DGX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the DGX SEC filings page. Lician reads the product cache first so this HTML stays unique to Quest Diagnostics Incorporated even when a live quote feed is slow.